about
Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging.Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor.Synthesis, Radiolabeling, and Biological Evaluation of 5-Hydroxy-2-[(18)F]fluoroalkyl-tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging.GABAA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [18F]flumazenil PET.Synthesis and biological evaluation of (18)F-labeled Fluoroethoxy tryptophan analogues as potential PET tumor imaging agents.Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging.Imaging tumour ATB0,+ transport activity by PET with the cationic amino acid O-2((2-[18F]fluoroethyl)methyl-amino)ethyltyrosine.Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor.Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain.5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET.18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization.In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors.Ligand selectivity for the acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes investigated by molecular docking.Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.Structure-activity relationships of fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) derivatives and the discovery of a high affinity analogue as a potential candidate for imaging metabotropic glutamate recepoSynthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks.Quantitative positron emission tomography of mGluR5 in rat brain with [(18) F]PSS232 at minimal invasiveness and reduced model complexity.Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5.Evaluation of [11C]Me-NB1 as a potential PET radioligand for measuring GluN2B-containing NMDA receptors, drug occupancy and receptor crosstalk.Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor.Development of [(18)F]-PSS223 as a PET tracer for imaging of metabotropic glutamate receptor subtype 5 (mGluR5).Synthesis and Pharmacological Evaluation of [11C]Granisetron and [18F]Fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging.Preclinical evaluation and test-retest studies of [(18)F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5).Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2.Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis.CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers.Novel chemoselective (18)F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions.Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules.Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice.Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [F]PSS232 in the Rat BrainSilicon-based building blocks for one-step 18F-radiolabeling of peptides for PET imagingSynthesis and binding studies of epibatidine analogues as ligands for the nicotinic acetylcholine receptorsSingle-step radiofluorination of peptides using continuous flow microreactorIdentification, characterization and suppression of side-products formed during the synthesis of high dose ⁶⁸Ga-DOTA-TATEPositron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous systemIdentification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor
P50
Q37127657-721214B5-3AC7-43EB-8EC6-3830888A7EAFQ37689804-DF86A88B-0F18-4AB1-8847-5976A0C919D7Q38770184-B6CF9E6F-4DCF-430C-971D-84E2DDD712A6Q38964192-F621B8DD-CE49-4D9F-8E67-EEC0194F3912Q38978731-A20766D1-24D2-4056-90D8-B568687987D2Q38997841-D1DF7D1E-80CF-4FAF-9A47-96EF31860490Q39048536-F5DED266-1FED-4C30-A848-0B58E7B08AF7Q39062639-4A9B441A-C01C-41D4-BDA6-FF287BA8D901Q39135834-02109DB2-EB51-4DD9-B49E-D5578310ADE9Q39166785-31B6C222-7D5E-47E7-8401-EE33DAD41410Q39397070-174F3A4C-3C9D-4268-ADAE-1BD83D752D93Q39608200-49ABA1DE-8A22-45FA-9F69-A172A71AFE71Q39624395-FF60F85E-3B1F-425A-AF74-8177B5D1F648Q39653227-86CC1BC4-F851-4AF9-AE1B-A3A9A5F9112FQ40389446-4ABCD3F2-9EF4-4E3D-AC14-E783E176965CQ41440952-3855CCB0-9C2A-48C4-8B76-1D73E3477041Q41563067-8D01F21C-4C38-458A-AAEB-68109EBCE3CEQ43089103-69D6AEB5-15B6-40D3-A38E-24AA1700BA1AQ44713796-B337458D-A546-47DC-AAD9-01044405E497Q46828950-7C456FC3-9E26-4935-BD4D-FE2D7E8E603EQ47432979-967E659B-7A15-4B72-829F-436367766E14Q47695530-87EE9324-5FF8-42A4-9480-62C0EAB1ED4BQ47941693-81F894AC-6952-4686-9989-CEDCD1D76158Q48189536-11F223FF-F7C7-49F7-B6A3-8EE211489CACQ48500618-8C8FBEF0-134B-4066-9C45-B457ED68A417Q48508292-A5B9158C-0CF7-4169-B8E3-7160101D9BBDQ48595216-9AEC6BB4-D738-4D54-960E-B0D14C83CF90Q48636242-CCD35416-39F1-4165-90A4-D4FEDAFD0EB4Q50944336-56879EDE-6054-40C2-9DB4-88EAAE695301Q51633536-000F4ADB-715D-4252-A4F3-94788190595EQ52983939-38271EAE-1F12-430D-9D4D-3C65DC043E86Q53065823-BEAECEB4-3651-4D90-AE95-35AEEEF76B00Q55385817-7CBB90F2-0559-4B27-A27B-B1EDBE55986CQ58692950-912ECFE0-B875-4806-BB53-998357C312F2Q81321213-DDD0DA1D-13A9-43BD-8CFB-B7AACA2B09F5Q82869892-4728968A-1696-4AE5-A811-628CE024FD6EQ84407358-3C076786-6D3F-403A-879C-49DE648958A5Q84913317-1434BE09-B636-4E69-BDBD-22E39B33BF2CQ89158399-94484BEA-4E9D-4BD0-952D-C0A6F551E9F2Q90374705-109E62EF-1813-4990-B044-39B6FF28311B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Linjing Mu
@en
Linjing Mu
@nl
type
label
Linjing Mu
@en
Linjing Mu
@nl
prefLabel
Linjing Mu
@en
Linjing Mu
@nl
P31
P496
0000-0001-5354-1546